

6. Literaturverzeichnis

1. Acreci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL (2005) Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 acute myeloid leukemia. *Blood* 106: 1183-1188
2. Adam C, Mysliwicz J, Mocikat R (2007) Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. *J transl med* 5: 16
3. Adams GP, Mei-Sheng T, McCartney JE, Marks JD, Stafford Iii WF, Houston LL, Huston JS, Weiner LM (2006) Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. *Clin Cancer Res* 12: 1599-1605
4. Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DN (2004) The immune response to breast cancer, and the case for DC immunotherapy. *Cytotherapie* 6: 154-165
5. Andrews RG, Torok-Storb B, Bernstein ID (1983) Myeloid-associate differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. *Blood* 62: 124-132
6. Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW (1986) The L4F3 antigen is expressed by unipotent and multipotent colonyforming cells but not by their precursors. *Blood* 68: 1030-1035
7. Andrews RG, Singer JW, Bernstein ID (1989) Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. *J Exp Med* 169: 1721-1731
8. Azuma Y, Ishikawa Y, Kawai S, Tsunenari T, Tsunoda H, Igawa T, Iida S, Nanami M, Suzuki M, Irie RF, Tsuchiya M, Yamada-Okabe H (2007) Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. *Clin Cancer Res*: 2745-2750

9. Bell M, Kamm M (2000) The clinical role of anti-TNF α antibody treatment in Crohn's disease. *Aliment Pharmacol Ther* 14: 501-514
10. Boes M, Esau C, Fischer MB, Schmidt T, Carroll M, Chen J (1998) Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. *J Immunol* 160: 4776-4787
11. Bokemeyer C, Panse J (2005) Passive Immuntherapie mit monoklonalen Antikörpern. *Onkologie* 28: 9-13
12. Borchman P, Riethmüller G, Engert A (2001) Monoklonale Antikörper: Entwicklung und klinische Perspektiven. *Internist (Berl)* 42: 803-814
13. Borsos T, Rapp HJ (1965) Complement fixation on cell surface by 19S and 7S antibodies. *Science* 150: 505-506
14. Borsos T, Rapp HJ (1965) Hemolysin titration based on fixation of the activated first component of complement evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. *J Immunol* 95: 559-566
15. Braendlein S, Pohle T, Ruoff N, Müller-Hermelink H-K, Vollmers P (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. *Clin Cancer Res* 63: 7995-8005
16. Braun J, Saxon A, Wall R, Morrison SL (1992) *The Second Century of the Antidody; Molecular Perspectives in Regulation, Pathophysiology and Therapeutic Applications*. *West J Med* 157: 158-168
17. Bredius RGM, Driedijk PC, Schouten MFJ, Weening RS, Out TA (1992) Complement Activation by Polyclonal Immunglobulin G1 and G2 against *Staphylococcus aureus*, *Haemophilus influenzae* Type b, and Tetanus Toxoid. *Infect Immun* 60: 4838-4847

18. Brethon B, Auvrignon A, Galambrun C, Yakouben K, Leblanc T, Bertrand Y, Leverger G, Baruchel A (2006) Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. *BMC Cancer* 28: 172
19. Bross PF, Beitz J, Chen G (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. *Clin Cancer Res* 7: 1490-1496
20. Burnette WN (1981) „Western blotting“: electrophoretic transfer of proteins from sodium dodecyl sulfate – polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. *Anal Biochem* 112 : 195-203
21. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. *Nat Rev Cancer* 1: 118-129
22. Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve Rituximab efficacy. *Blood* 104: 2635-2642
23. Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. *Mol Cell Biol* 7: 2745-2752
24. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med* 6: 443-446
25. Collins C, Tsui FWL, Shulman M (2002) Differential activation of human and guinea pig complement by pentameric and hexameric IgM. *Eur J Immunol* 32: 1802-1810
26. Cooper NR (1985) The classical complement pathway: activation and regulation of the first complement component. *Adv Immunol* 37: 151
27. Countouriotis A, Moore TB, Sakamoto KM (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. *Stem Cells* 20: 215-229

28. Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, French RR, Glennie MJ (2003) Complement-mediated lysis by anti-CD20 monoclonal antibodies correlates with segregation into lipid rafts. *Blood* 101: 1045-1052
29. Dantas-Barbosa C, Brigido MM, Maranhao AQ (2005) Construction of a human Fab phage display library from antibody repertoires of osteosarcoma patients. *Genet Mol Res* 4: 126-140
30. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H (1989) CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. *J Exp Med* 170: 637
31. Davis AC, Roux KH, Shulman MJ (1988) On the structure of polymeric IgM. *Eur. J Immunol* 18: 1001-1008
32. Davis AC, Roux KH, Pursay J, Shulman MJ (1989) Intermolecular disulfide bonding in IgM: effect of replacing cysteine residues in the μ heavy chain. *EMBO J* 8: 2519-2526
33. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V (2005) Platelet activation leads to activation and propagation of the complement system. *J Exp Med* 201: 871-879
34. Dillman RO (1994) Antibodies as cytotoxic therapy. *J Clin Oncol* 12: 1497-1515
35. Dillman RO (2001) Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. *Cancer Invest* 19: 833-841
36. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. *Blood* 67: 1048-1053

37. Dvorak HF, Nagy JA, Dvorak AM (1991) Structure of solid tumors and their vasculature: implications for the therapy with monoclonal antibodies. *Cancer Cells* 3: 77-85
38. Dyer MJ, Hale G, Hayhoe FG, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. *Blood* 73: 1431-1439
39. Ellerson JR, Yasmeen D, Painter RH, Dorrington KJ (1976) Structure and function of immunoglobulin domains. Isolation and characterization of a fragment corresponding to the Cgamma2 homology region of human immunoglobulin G1. *J Immunol* 116: 510-517
40. Estey E, Thall P, Giles F, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM (2002) Gemtuzumab ozogamicin with or without interleukin II in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. *Blood* 99: 4343-4349
41. Golay J, Manganini M, Rambaldi A, Intrara M (2004) Effect of alemtuzumab on neoplastic B cells. *Haematologica* 89: 1476-1483
42. Goldlust MB, Shin HS, Hammer CH, Mayer MM (1974) Studies of complement complex C5b, 6 eluted from EAC-6: reaction of C5, 6 with EAC4b, 3b and evidence on the role of C2a and C3b in the activation of C5. *J Immunol* 113: 998-1007
43. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. *Leuk Res* 8: 521-534
44. Graziano RF, Ranger MW (1987) Fcγ RI and Fcγ RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. *J Immunol* 139: 3536-3541

-
45. Hoon DS, Wang Y, Sze L, Kanda H, Watanabe T, Morrison SL, Morton DL, Irie RF (1993) Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. *Cancer Res* 53: 5244
 46. Hudson PJ, Souriau C (2003) Engineered antibodies. *Nat Med* 9: 129-134
 47. Hughes-Jones NC, Gardner B (1979) Reaction between the isolated subunits of the complement component C1q and IgG-complexes. *Mol Immunol* 16: 697
 48. Hughey CT, Brewer JW, Colosia AD, Rosse WF, Corley RB (1998) Production of IgM hexamers by normal and autoimmune B cells: Implications for the physiologic role of hexameric IgM. *J Immunol* 161: 4091-4097
 49. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG (2000) Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc. *J Immunol* 164: 4178-4184
 50. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG (2001) Engineered Antibodies with Increased Activity to Recruit Complement. *J Immunol* 166: 2571-2575
 51. Imai M, Landen C, Ohta R, Cheung N-KV, Tomlinson S (2005) Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. *Cancer Res* 65: 10562-10568
 52. Irie RF, Ollila DW, O'Day S, Morton DL (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. *Cancer Immunol Immunother* 53: 110-117
 53. Ishizaka T, Tada T, Ishizaka K (1968) Fixation of C and C1a by rabbit gamma-G- and gamma-M-antibodies with particulate and soluble antigens. *J Immunol* 100: 1145-1153

-
54. Jain RK, Baxter LT (1988) Mechanismus of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. *Cancer Res* 48: 7022-7032
 55. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Thomas D, Keating M, Freireich E, Albitar M (2002) Differences in CD33 intensity between various myeloid neoplasms. *Am J Clin Pathol* 118: 560-566
 56. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. *J Natl Cancer Inst* 66: 249
 57. Kennedy AD, Beum PV, Solga MD, Dilillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. *J Immunol* 172: 3280-3288
 58. Kim SJ, Park Y, Hong HJ (2005) Antibody Engineering for the Development of Therapeutic Antibodies. *Mol Cells* 20: 17-29
 59. Klein M, Haeffner-Cavaillon N, Isenman DE, Rivat C, Navia MA (1981) Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region. *Proc Natl Acad Sci* 78: 524-528
 60. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256: 495-497
 61. Koshland ME (1985) The coming of age of the immunoglobulin J-chain. *Annu Rev Immunol* 3: 425-453
 62. Kownatzki E (1973) Reassociation of IgM subunits in the presence and absence of J chain. *Immunol Commun* 2: 105
 63. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685

-
64. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. *Proc Natl Acad Sci* 130: 4005-4010
 65. Lazzarino M, Arcini L, Orlandi E, Iacona I, Bernasconi P, Calatroni S, Varettoni M, Isa L, Brusamolini E, Bonfichi M, Passamonti F, Burcheri S, Pascutto C, Regazzi M (2005) Immunochemotherapie with Rituximab, Vincristine and 5-Day Cyclophosphamid for Heavily Pretreated Follicular Lymphoma. *Oncology* 68: 146-153
 66. Li J, Sai T, Berger M, Chao Q, Davidson D, Deshmukh G, Drozdowski B, Ebel W, Harley S, Henry M, Jacob S, Kline B, Lazo E, Rotelle F, Routhier E, Rudolph K, Sage J, Simon P, Yao J, Zhou Y, Kavuru M, Bonfield T, Thomassen MJ, Sass PM, Nicolaides NC, Grasso L (2006) Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. *Proc Natl Acad Sci* 103: 3557-3562
 67. Liao JCF, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergmann PJ (2006) Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. *Cancer Immun* 6:8
 68. Maniatis A, Tsakanikas S, Stamatellou M, Papanastasiou K (1989) Intermediate-dose melphalan for refractory myeloma. *Blood* 74:1177
 69. Martin NH (1968) Macroglobulinämia. *Clin Chim Acta* 22: 15-25
 70. Martin NH (1969) The immunoglobulins: A review. *J Clin Pathol* 22: 117-131
 71. Meissner P, Pick H, Kulangara A, Chatellard P, Friedrich K, Wurm FM (2001) Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells. *Biotechnol Bioeng* 75: 197-203
 72. Michaelsen TE, Brekke OH, Aase A, Sandin RH, Bremnes B, Sandlie I (1994) One disulfide bond in front of the second heavy chain constant region is necessary and

- sufficient for effector functions of human IgG3 without a genetic hinge. *Proc Natl Acad Sci* 91: 9243-9247
73. Mohindru M, Verma a (2005) Engineered antibodies act as targeted therapies in cancer treatment. *Indian J Pediatr* 72: 943-947
 74. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules; mouse antigen-binding domains with constant region domains. *Proc Natl Acad Sci* 21: 6851-6855
 75. Mostov KE (1994) Transepithelial transport of immunoglobulins. *Annu Rev Immunol* 12: 63-84
 76. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmaso AP (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay accelerating factor), and CD59 (protectin). *Am J Pathol* 194: 129-142
 77. Okada N, Yin S, Asai S, Kimbara N, Dohi N, Hosokawa M, Wu X, Okada H (2005) Human IgM monoclonal antibodies reactive with HIV-1-infected cells generated using a trans-chromosome mouse. *Microbiol Immunol* 49: 447-459
 78. Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L, Wolchok JD, Houghton AN, Gregor PD (2007) Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a flt-3 ligand fusion vaccine. *Cancer res* 13: 1-18
 79. Ortin M (2005) Immunotherapy of hematological malignancies: what is new? *Ann Oncol* 16: 53-62
 80. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapie with peptide-based vaccines: what have we achieved? Where are we going? *J Natl Cancer Inst* 94: 805-818

81. Paukovits P, Himmeler G, Loibner H (2004) Immunotherapie of malignant diseases- developments and prospects. *Wien Med Wochenschr* 154: 235-241
82. Peterson HI (eds) (1979) Tumor blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumors. CRC Press, Inc., Boca Raton, pp 77-85
83. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 7: 357-359
84. Poon PH, Morrison SL, Schumaker VN (1995) Structure and function of several anti-dansyl chimeric antibodies formed by domain interchanges between human IgM and mouse IgG2b. *J Biol Chem* 270: 8571-8577
85. Porath J (1988) High-performance immobilized-metal-ion affinity chromatography of peptides and proteins. *J Chromatogr* 443: 3-11
86. Raab G, Eiermann W (2001) Trastuzumab, ein neuer Behandlungsansatz beim Mammakarzinom. *Internist (Berl.)* 42: 835-842
87. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO (2005) Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. *J Immunol* 174: 5706-5712
88. Randall TD, King LB, Corley RB (1990) The biological effects of IgM hexamer formation. *Eur J Immunol* 20: 1971-1979
89. Randall TD, Brewer JW, Corley RB (1992) Direct evidence that J chain regulates the polymeric structure of IgM in antibody-secreting B cells. *J Biol Chem* 267: 18002-18007

-
90. Ravandi F, Kantarjian H, Cortes J (2004) New agents in acute myeloid leukemia and other myeloid disorders. *Cancer* 100: 441-454
 91. Repp R, Valerius T, Bargou R (2001) Bispezifische Antikörper in der Hämatologie und Onkologie. *Internist (Berl.)* 42: 854-859
 92. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, Edwin S, Kim YM, Hong J-S, Mazor M (2005) Normal pregnancy is characterized by systemic activation of the complement system. *J Matern Fetal Neonatal Med* 17: 239-245
 93. Ries LA, Eisner MP, Kosary CL (2000) SEER Cancer Statistics Review, 1973-1997. Table XIII-5 Acute Myeloid Leukemia. Bethesda, MD: National Cancer Institute
 94. Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhati M, Bradley B, Del Toro G, George D, Garvin J, Van De Ven C, Cairo MS (2005) Preliminary results of the safety of immunotherapy with Gemtuzumab Ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. *Clin Cancer Res* 11: 7164-7170
 95. Rosen FS, Steiner LH, Unanue ER (eds) (1989) *Macmillan Dictionary of Immunology*. New York: The Macmillan Press, Ltd.
 96. Ruffner KL, Matthews DC (2000) Current uses of monoclonal antibodies in the treatment of acute leukemia. *Semin Oncol* 27: 531-539
 97. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N (1985) Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 230: 1350-1354
 98. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci USA* 74: 5463-5467

-
99. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L (2005) Antibody engineering: facing new challenges in cancer therapy. *Acta Pharmacol Sin* 26: 641-648
 100. Satthaporn S, Eremin O (2001) Dendritic cells (II): Role and therapeutic implication in cancer. *J R Coll Surg Edinb* 46: 159-167
 101. Schäffner G, Kabelitz D (2001) Monoklonale Antikörper zur Therapie. *Dtsch Med Wochenschr* 126: 851-856
 102. Schreiber AD, Frank MM (1972) Role of antibody and complement in the immune clearance and destruction of erythrocytes. *J Clin Invest* 51: 575-581
 103. Seo N, Furunkawa F, Tokura Y, Takigawa M (2003) Vaccine therapy for cutaneous T-cell lymphoma. *Hematol Oncol Clin North Am* 17: 1467-1474
 104. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. *Cancer Immunol Immunother* 48: 673-683
 105. Soling A, Rainor NG (2001) Dendritic cell therapy of primary brain tumors. *Mol Med* 7: 659-667
 106. Svehag SE, Manheim L, Bloth B (1972) Ultrastructure of human C1q protein. *Nat New Biol* 238: 117-118
 107. Tao M-H, Smith RIF, Morrison SL (1993) Structural Features of Human Immunglobulin G that Determine Isotype-specific Differences in Complement Activation. *J Exp Med* 178: 661-667
 108. Teeling JL, French RR, Cragg MS, Van Den Brakel J, Pluyter M, Chan C, Parren PWHI, Hack CE, Dechant M, Valerius T, Van De Winkel JGJ, Glennie MJ (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. *Blood* 104: 1793-1800

-
109. Tomizuka K, Shinohara T, Yoshida H, Uejima H, Ohguma A, Tanaka S, Sato K, Oshimura M, Ishida I (2000) Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. *Proc Natl Acad Sci* 97: 722-727
 110. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignances. *J Immunother* 24: 263-271
 111. Tsimberidou A-M, Giles F, Estey E, O'Brien S, Keating MJ, Kantarjian HM (2005) The role of gemtuzumab ozogamicin in acute leukaemia therapy. *Br J Haematol* 132: 398-409
 112. Van Dongen GA, Visser GW, Lub-de Hooge MN, d Vries EG, Perk LR (2007) Immuno-PET: a navigator in monoclonal antibody development and applications. *Oncologist* 12: 1379-1389
 113. Vollmers HP, O'Connor R, Müller J, Kirchner T, Müller-Hermelink HK (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. *Cancer Res* 49: 2471-2476
 114. Vollmers HP, Dämmrich J, Ribbert H, Grassel S, Debus S, Heeseman J, Müller-Hermelink HK (1994) Human monoclonal antibodies from stomach carcinoma patients react with *Helicobacter pylori* and stimulate stomach cancer cells in vitro. *Cancer* 74: 1525-1532
 115. Vollmers HP, Dämmrich J, Hensel F, Ribbert H, Meyer-Bahlburg A, Ufken-Gaul T, Korff M, Müller-Hermelink HK (1997) Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. *Cancer* 79: 433-440
 116. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Rückle-Lanz H, Reindl L, Müller-Hermelink HK (1998) Adjuvant therapy for gastric adenocarcinoma with the apoptosisinducing human monoclonal antibody SC-1: first clinical histopathological results. *Oncol Rep* 5: 549-552

-
117. Vollmers HP, Braendlein S (2002) Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. *Hum Antibodies* 11: 131-142
 118. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID (2005) Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. *Blood* 105: 1295-1302
 119. Wang HC, Yang MH, Shi YY, Pang XW, Yang XW, Yang XA, Peng JR, Leng XS, Chen WF (2005) Screening and analysis of genes encoding hepatocellular carcinoma associated tumor antigens. *Zhonghua Gan Zang Bing Za Zhi* 13: 343-346
 120. Wiersma EJ, Collins C, Fazel S, Shulman M (1998) Structural and functional analysis of J chain-deficient IgM. *J Immunol* 160: 5979-5989
 121. Wigler M, Silverstein S, Lee LS, Pellicer A, Cheng Y, Axel R (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. *Cell* 11: 223-232
 122. Winkler U, Jensen M, Manzke O (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody. *Blood* 94: 2217-2224
 123. Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J (2005) Comparison of rituximab plus CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. *Ai Zheng* 24: 1498-502
 124. Xia MQ, Hale G, Waldmann H (1993) Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. *Mol Immunol* 30: 1089-1096
 125. Zein N, Sinha AM, McGahren WJ, Ellestad GA (1988) Calceamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. *Science* 240: 1198-1201